Prot #EPZ-5676-12-001: A Phase 1, Open-Label, Dose Escalation and Expanded Cohort, Continuous Intravenous Infusion, Multicenter Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EPZ-5676 in Treatment Relapsed/Refractory Patients

Project: Research project

Project Details

StatusFinished
Effective start/end date7/22/137/22/16

Funding

  • Epizyme, Inc. (Prot #EPZ-5676-12-001)